Swedish/Danish Biotech Company 2A Pharma Raises SEK 27 Million and Signs Exclusive Worldwide License Agreement

Document -

Swedish/Danish Biotech Company 2A Pharma Raises SEK 27 Million and Signs Exclusive Worldwide License Agreement

  • License: © All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .pdf

Contacts

Søren Nielsen

Press contact CEO +45 2539 4137

Related content

Swedish/Danish Biotech Company 2A Pharma Raises SEK 27 Million and Signs Exclusive Worldwide License Agreement

New Swedish/Danish biotech company 2A Pharma AB has closed its first financing round and has been granted an exclusive, worldwide license from Medigene AG (FSE: MDG1) for its adeno-associated virus like particles (AAVLPs) technology.
Malmö, Sweden, 16 January 2016. 2A Pharma AB, based in Malmö, Sweden with research facilities in Aalborg, Denmark, aims to develop novel, cost effective vaccines a